CTCA Common terminology criteria for adverse events
SAE Severe adverse event
AE adverse event
SF Shortening fraction
MAPK Mitogen activated protein kinase
NF1 Neurofibromatosis type 1
LGG Low grade gliomas
HGG High grade gliomas
LCH Langerhance cell histiocytosis
MAKER MEK inhibitors associated retinopathy
BMI Boddy mass index
JPA Juvenile pilocytic astrocytoma
GBM Glioblastoma multiforme
PXA Pleomorphic Xanthoastrocytoma
PLEVA Pityriasis Lichenoides et Variolifomis acuta
SCC Squamous cell carcinoma
GH Growth hormone
DEXA Dual energy Xray absorptiometry
TBS Trabecular bone score
LVSF Left ventricular fractional shortening
AMN Acute macular neuroretinopathy
OCT Optical coherence tomography
EN Erythema nodosum
N# NUMBER